Holen Sie sich die Stockscreener-App
25.34
2.50%
-0.65
Handel nachbörslich:
25.95
0.61
+2.41%
Schlusskurs vom Vortag:
$25.99
Offen:
$25.55
24-Stunden-Volumen:
125.92K
Relative Volume:
0.27
Marktkapitalisierung:
$351.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.48M
KGV:
-17.31
EPS:
-1.4641
Netto-Cashflow:
$-8.59M
1W Leistung:
-2.09%
1M Leistung:
-9.89%
6M Leistung:
+143.65%
1J Leistung:
+138.38%
1-Tages-Spanne:
$25.02
$26.85
1-Wochen-Bereich:
$23.85
$27.21
52-Wochen-Spanne:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
25.34 | 360.08M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
Aug Analyst Calls: What are the future prospects of Greenwich LifeSciences IncPortfolio Value Summary & Real-Time Market Trend Scan - baoquankhu1.vn
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
If You Invested $1,000 in Greenwich Lifesciences Inc (GLSI) - Stock Titan
Retail Trends: Is Greenwich LifeSciences Inc undervalued by DCF analysisGold Moves & Weekly Top Performers Watchlists - baoquankhu1.vn
Treasury Yields: Is Greenwich LifeSciences Inc a turnaround storyWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Greenwich LifeSciences expands Phase III trial to City of Hope sites - Investing.com Canada
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope - National Today
Greenwich LifeSciences expands Phase III trial to City of Hope sites By Investing.com - Investing.com India
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 - ChartMill
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com South Africa
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - The Manila Times
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - GlobeNewswire Inc.
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com South Africa
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 - The Manila Times
Greenwich LifeSciences Provides Update Showing Continued - GlobeNewswire
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com Australia
Breast cancer trial sees under 1% yearly recurrences in GLSI-100 arm - Stock Titan
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewswire
Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
GLSI Should I Buy - Intellectia AI
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Greenwich LifeSciences reports 33% rise in trial screening rate By Investing.com - Investing.com Canada
Greenwich LifeSciences reports 33% rise in trial screening rate - Investing.com South Africa
Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial - Traders Union
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - GlobeNewswire
US Stocks Recap: Is Greenwich LifeSciences Inc undervalued by DCF analysisTrade Exit Summary & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):